SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Ocular Therapeutix, Inc. (OCUL)

NEW YORK, July 7, 2017 /PRNewswire/ -- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Ocular Therapeutix, Inc. ("Ocular" or the "Company") (NASDAQ: OCUL). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/ocul.

The investigation concerns whether Ocular and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

On May 5, 2017, Ocular revealed that the U.S. Food and Drug Administration found issues at its manufacturing plant. Then on July 6, 2017, Seeking Alpha reported that Ocular's management has been misleading investors about its manufacturing issues, including that more than half of lots manufactured by Ocular contain bad product. Following this news, Ocular stock dropped $0.68 per share or over 6% to close at July 6, 2017.

If you are aware of any facts relating to this investigation, or purchased shares of Ocular, you can assist this investigation by visiting the firm's site: www.bgandg.com/ocul. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration.   Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | [email protected]

SOURCE Bronstein, Gewirtz & Grossman, LLC

Related Links

http://www.bgandg.com